Oral piretanide in chronic renal failure.
1 The effects of high doses of piretanide, a new diuretic agent chemically related to frusemide and bumetanide were evaluated in twelve patients with severe chronic renal insufficiency (creatinine clearance below 25 ml/min). 2 Patients received either 30 mg or 60 mg piretanide orally after a water load of 11. Urine volume and the excretion of electrolytes, creatinine, urea and uric acid were measured over the subsequent 24 h. 3 Piretanide produced an effective diuresis and natriuresis in these patients, its action being broadly similar to those of bumetanide and frusemide observed in previous studies.
D000328:Adult; D000368:Aged; D002034:Bumetanide / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D004573:Electrolytes / Q000652:urine; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000652:urine; D013449:Sulfonamides / Q000627:therapeutic use*
D004232:Diuretics; D004573:Electrolytes; D013449:Sulfonamides; D002034:Bumetanide; D005665:Furosemide; D012964:Sodium; C015451:piretanide